Second-generation antipsychotics: Cost-effectiveness, policy options, and political decision making

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 515-520

  Rosenheck, Robert A ^a   Leslie, Douglas L ^b   Doshi, Jalpa A ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CONSUMER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG TOLERABILITY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; METABOLIC SYNDROME X; POLITICS; PUBLIC HEALTH; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; DECISION MAKING; DYSKINESIA, DRUG-INDUCED; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; PATIENT ADVOCACY; POLICY MAKING; POLITICS; SCHIZOPHRENIA; UNITED STATES;

EID: 49749099137     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.59.5.515     Document Type: Review

References (76)

1. Redbook. Montvale, NJ, Thomson, 2004
2. Vital signs: Seroquel led antipsychotics sales in 2006. Clinical Psychiatry News 35(5): 1, 2007
3. Huskamp HA: Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value. Health Affairs 25:635-646, 2006
4. Heres S, Davis J, Maino K, et al: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163: 185-194, 2006
5. Montgomery JH, Byerly M, Carmody T, et al: An analysis of the effect of funding source in randomized clinical trials of second-generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 25: 598-612, 2004
6. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289:454-465, 2003
7. Harris G: Psychiatrists top list in drug maker gifts. New York Times, June 27, 2007, p 1
8. Fox J: Medicare should, but cannot, consider cost: legal impediments to a sound policy. Buffalo Law Review 53:577-633, 2005
9. Gray V, Lowery D, Godwin EK: The political management of managed care: exploring variations in state health maintenance organization regulations. Journal of Health Policy, Politics, and Law 32:457-495, 2007
10. Stone D: Policy Paradox: The Art of Political Decision Making, revised ed. New York, Norton, 2001
11. Scully JH, Wilk JE: Selected characteristics and data of psychiatrists in the US, 2001-2002. Academic Psychiatry 27:247-251, 2003
12. Occupational Outlook Handbook. Washington, DC, US Department of Labor, Bureau of Labor Statistics. Available at www.bls.gov/oco/ocos074.htm. Accessed May 2, 2007
13. Frank RG, Glied S: Better but Not Well: Mental Health Policy in the United States since 1950. Baltimore, Johns Hopkins University Press, 2006
14. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553-564, 2003
15. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry 161:414-425, 2004
16. Hamilton SH, Revicki DA, Edgell ET, et al: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial. Pharmacoeconomics 15:469-480, 1999
17. Carpenter WT, Thaker GK: Editorial: evidence-based therapeutics: introducing the Cochrane Corner. Schizophrenia Bulletin 33:633-634, 2007
18. Rosenheck RA, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 290:2693-2702, 2003
19. Rosenheck RA: Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatric Services 56:85-92, 2005
20. Hugenholtz GWK, Heerdink ER, Stolker JJ, et al: Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. Journal of Clinical Psychiatry 67:897-903, 2006
21. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. New England Journal of Medicine 353:1209-1223, 2005
22. Rosenheck RA, Leslie D, Sindelar J, et al: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163: 2080-2089, 2006
23. Keefe RSE, Bilder RM, Davis SM, et al: Archives of General Psychiatry 64:633-647, 2007
24. Swartz M, Perkins D, Stroup S, et al: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. American Journal of Psychiatry 164: 428-436, 2007
25. Rosenheck RA, Swartz M, McEvoy J, et al: Changing perspectives on second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research 7(2):103-111, 2007
26. Jones PB, Barnes TR, Davies L, et al: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006
27. Kane JM, Meltzer HY, Carson WH, et al: Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 68:213-223, 2007
28. Rosenheck RA: Aripiprazole vs perphenazine: no difference (letter). Journal of Clinical Psychiatry 68:1812, 2007
29. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
30. Freedman D: The choice of antipsychotic drugs for schizophrenia. New England Journal of Medicine 353:1286-1288, 2005
31. Halliday J, Farrington S, Macdonald S, et al: Nithsdale Schizophrenia Surveys 23: movement disorders - 20-year review. British Journal of Psychiatry 181:422-427, 2002
32. Rochon PA, Stukel TA, Sykora K, et al: Atypical antipsychotics and parkinsonism. Archives of Internal Medicine 165:1882-1888, 2005
33. Woods S, Saksa JR, Walsh B, et al: Tardive dyskinesia in a community mental health center: 2000-2005. Presented at the Institute on Psychiatric Services, San Diego, Oct 5-9, 2005
34. Lee PE, Sykora K, Gill SS, et al: Antipsychotic medication and drug-induced movement disorder: a population-based cohort study in older adults. Journal of the American Geriatrics Society 53:1374-1379, 2005
35. Rosenheck RA: Considerations for evaluating the cost-effectiveness of reducing tardive dyskinesia with second-generation antipsychotics. British Journal of Psychiatry 191: 238-245, 2007
36. Neumann PJ: Using Cost-Effectiveness Analysis to Improve Health Care. New York, Oxford University Press, 2005
37. Polsky D, Doshi JA, Bauer MS, et al: Clinical trial-based cost-effectiveness analyses of antipsychotic use. American Journal of Psychiatry 163:2047-2056, 2006
38. Davies LM, Lewis S, Jones PB, et al: Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 191:14-22, 2007
39. Duggan M: Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 24:1-31, 2005
40. Rosenheck RA, Leslie DL, Sernyak ME: From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Medical Care 39:302-308, 2001
41. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Comparative Effectiveness Review No 6. Rockville, Md, US Department of Health and Human Services, Agency for Health Care Research and Quality, 2007. Available at effectivehealthcare.ahrq.gov/repFiles/ AtypicalAntipsychoticsFinalReport.pdf
42. Freedman R, Carpenter WT, Davis JM, et al: The cost of drugs for schizophrenia. American Journal of Psychiatry 163:2029-2031, 2006
43. Hoadley J: Cost Containment Strategies for Prescription Drugs: Assessing the Evidence in the Literature. Washington, DC, Georgetown University, Health Policy Institute, 2005. Available at www.kff.org/rxdrugs/7295.cfm
44. Weisfeldt ML, Zieman SJ: Advances in the prevention and treatment of cardiovascular disease. Health Affairs 26:25-37, 2007
45. Rice T, Matsuoka KY: The impact of costsharing on appropriate utilization and health status: a review of the literature on seniors. Medical Care Research and Review 61:415-452, 2004
46. Gibson TB, Ozminkowski RJ, Goetzel RZ: The effects of prescription drug cost sharing: a review of the evidence. American Journal of Managed Care 11:730-740, 2005
47. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007
48. Goldman DP, Joyce GF, Escarce JJ, et al: Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291:2344-2350, 2004
49. Huskamp HA, Deverka PA, Epstein AM, et al: Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Archives of General Psychiatry 62:435-441, 2005
50. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331:650-655, 1994
51. Huskamp HA, Epstein AM, Blumenthal D: The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Affairs 22(3):149-158, 2003
52. Pharmaceutical Bulk Purchasing: Multi-state and Inter-agency Plans. Washington, DC, National Conference of State Legislatures, 2008. Available at www.ncsl.org/programs/health/bulkrx.htm
53. Duggan M, Scott-Morton F: The distortionary effects of government procurement: evidence for Medicaid prescription drug purchasing. Quarterly Journal of Economics 121:1-31, 2006
54. Huskamp HA, Shinogle JA: Potential effects of the new Medicare drug benefit on pricing for psychotropic medications. Psychiatric Services 56:1056-1058, 2005
55. Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices. Washington, DC, US Department of Health and Human Services, Office of Inspector General, 2005. Available at oig.hhs.gov/oei/reports/oei-03-05-00200. pdf. Accessed Nov 23, 2005
56. Epstein RA: Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation. New Haven, Conn, Yale University Press, 2006
57. Danzon PM, Wang RY, Wang L: The Impact of Price Regulation on the Launch Delay of New Drugs: Evidence From Twenty-Five Major Markets in the 1990s. Working paper 9874. Cambridge, Mass, National Bureau of Economic Research, 2003. Available at www.nber.org/papers/9874
58. Mossialos E, Oliver A: An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Planning and Management 20:291-306, 2005
59. Editorial: comparing schizophrenia drugs. New York Times, Sept 21, 2005. Available at www.nytimes.com/2005/09/21/opinion/21wed3.html?ex= 1183953600&en=1cadcb61b264f0c5&ei=5070
60. Vedantam S: New antipsychotic drugs criticized: federal study finds no benefit over older, cheaper drug. Washington Post, Sept 20, 2005, A1
61. Carey B: Study finds little advantage in new schizophrenia drugs. New York Times, Sept 20, 2005, p F1
62. Saul S: In some states, maker oversees use of its drug. New York Times, Mar 23, 2007. Available at www.nytimes.com/2007/03/23/business/23lilly.html?ex= 1183694400&en=3410c25dd672f388&ei=5070.
63. Pharmcaeutical Benefits Under State Medical Assistance Programs-2004. Reston, Va, National Pharmaceutical Council, 2004. Available at www.npcnow.org/resources/pharmbenefitsmedicaid.asp
64. The Medicaid Program at a Glance. Kaiser Commission on Medicaid and the Uninsured, 2005. Available at www.kff.org/medic aid/upload/the-medicaid-program- at-a-glan ce-fact-sheet.pdf
65. Huskamp HA, Stevenson DG, Donohue JM, et al: Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatric Services 58:308-310, 2007
66. Harris G: states try to limit drugs in Medicaid, but makers resist. New York Times, Dec 18, 2003. Available at query.nytimes.com/gst/fullpage.html?sec= health&res=9c02e1d7163ff93ba25751c1a9659c8b63
67. Sharfstein S: Antipsychotics, economics and the press. Psychiatric News 40(23):3, 2005
68. Moffic HS: My New Year's ethical resolutions. Clinical Psychiatry News 35(1):48, 2007
69. Ganguli R, Strassnig M: Are older antipsychotic drugs obsolete? No. British Medical Journal 332:1346-1347, 2006
70. Rosenheck RA, Leslie DL, Busch S, et al: Rethinking antipsychotic formulary policy. Schizophrenia Bulletin 34:375-380, 2008
71. Moore TA, Buchanan RW, Buckley PF, et al: The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 update. Journal of Clinical Psychiatry 68:1751-1762, 2007
72. Havel JT: Associations and public interest groups as advocates. Administration and Policy in Mental Health 20:27-44, 1992
73. Stockdill JW: A government manager's view of mental health advocacy groups. Administration and Policy in Mental Health 20:45-56, 1992
74. Ross EC: Success and failure of advocacy groups. Administration and Policy in Mental Health 20:57-66, 1992
75. Reinhardt UE: Perspectives on the pharmaceutical industry. Health Affairs 20(5):136-149, 2001
76. Rosenheck RA: The growth of psychopharmacology in the 1990s: evidence-based practice or irrational exuberance. International Journal of Law and Psychiatry 28:467-483, 2005